MXPA02006329A - Substituted 8arylquinoline phosphodiesterase4 inhibitors. - Google Patents
Substituted 8arylquinoline phosphodiesterase4 inhibitors.Info
- Publication number
- MXPA02006329A MXPA02006329A MXPA02006329A MXPA02006329A MXPA02006329A MX PA02006329 A MXPA02006329 A MX PA02006329A MX PA02006329 A MXPA02006329 A MX PA02006329A MX PA02006329 A MXPA02006329 A MX PA02006329A MX PA02006329 A MXPA02006329 A MX PA02006329A
- Authority
- MX
- Mexico
- Prior art keywords
- c1c6alkyl
- c0c6alkyl
- aryl
- heteroaryl
- son
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Novel substituted 8arylquinolines represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein S1, S2 and S3 are independently H, OH; halogen, C1C6alkyl, NO2, CN, or C1C6alkoxy, wherein the alkyl and alkoxy groups are optionally substituted with 15 substituents; wherein each substituent is independently a halogen or OH; R1 is a H, OH, halogen, carbonyl, or C1C6alkyl, cycloC3C6alkyl, C1C6alkenyl, C1C6alkoxy, aryl, heteroaryl, CN, heterocycloC3C6alkyl, amino, C1C6alkylamino, (C1C6alkyl)(C1C6alkyl)amino, C1C6alkyl(oxy)C1C6alkyl, C(O)NH(aryl), C(O)NH(heteroaryl), SOnNH(aryl), SOnNH(heteroaryl), SOnNH(C1C6alkyl), C(O)N(C0C6alkyl) (C0C6alkyl), NHSOn(C1C6alkyl), SOn(C1C6alkyl), (C1C6alkyl)OC(CN)dialkylamino, or (C1C6alkyl)SOn(C1C6alkal) group, wherein any of the groups is optionally substituted with 15 substituents; wherein each substituent is independently a halogen, OH, CN, C1C6alkyl, cycloC3C6alkyl, C(O)(heterocycloC3C6alkyl), C(O)O(C0C6alkyl), C(O)aryloxy, C1C6alkoxy, (C0C6alkyl)(C0C6alkyl)amino, cycloalkyloxy, acyl, acyloxy, cycloC3C6alkyl, heterocycloC3C6alkyl, aryl, heteroaryl, carbonyl, carbamoyl, or SOn(C1C6alkyl); A is CH, Cester, or CR4; R2 and R3 independently is an aryl, heteroaryl, H, halogen, CN, C1C6alkyl, heterocycloC36alkyl, C1C6alkoxy, carbonyl, carbamoyl, C(O)OH, C1C6alkyl)SOn(C1C6alkyl), C(O)N(C0C6alkyl)(C0C6alkyl), or C1C6alkylacylamino group, wherein any of the groups is optionally substituted with 15 substituents, wherein each substituent is independently an aryl, heteroaryl, halogen, NO2, C(O)OH, carbonyl, CN, C1C6alkyl, SOn(C1C6alkyl), SOn(aryl), aryloxy, heteroaryloxy, C1C6alkoxy, Noxide, C(O)heterocycloC3C6alkyl, NHcycloC3C6alkyl, amino, OH, or (C0C6alkyl)(C0C6alkyl)amino, C(O)N(C0C6alkyl)(C0C6alkyl) substituent group, wherein each substituent group independently is optionally substituted with OH, C1C6alkoxy, C1C6alkyl, cycloC3C6alkyl, aryloxy, C(O)OH, C(O)O(C1C6alkyl), halogen, NO2, CN, SOn(C1C6alkyl), or C(O)N(C0C6alkyl)(C0C6alkyl); one of R2 and R3 must be an aryl or heteroaryl, optionally substituted; when R2 and R3 are both an aryl or heteroaryl, then R2 and R3 may be optionally connected by a thio, oxy, or (C1C4alkyl) bridge to form a fused three ring system; are PDE4 inhibitors.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17152299P | 1999-12-22 | 1999-12-22 | |
| PCT/CA2000/001559 WO2001046151A1 (en) | 1999-12-22 | 2000-12-20 | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02006329A true MXPA02006329A (en) | 2004-05-14 |
Family
ID=22624050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02006329A MXPA02006329A (en) | 1999-12-22 | 2000-12-20 | Substituted 8arylquinoline phosphodiesterase4 inhibitors. |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1244628A1 (en) |
| JP (1) | JP3782011B2 (en) |
| KR (1) | KR20020082839A (en) |
| CN (1) | CN1221534C (en) |
| AR (1) | AR029214A1 (en) |
| AU (1) | AU778531B2 (en) |
| BG (1) | BG65403B1 (en) |
| BR (1) | BR0016651A (en) |
| CA (1) | CA2393749C (en) |
| CO (1) | CO5261613A1 (en) |
| CZ (1) | CZ20022171A3 (en) |
| DZ (1) | DZ3244A1 (en) |
| EA (1) | EA004747B1 (en) |
| EE (1) | EE200200342A (en) |
| GE (1) | GEP20053626B (en) |
| HK (1) | HK1057560A1 (en) |
| HR (1) | HRP20020545A2 (en) |
| HU (1) | HUP0203896A3 (en) |
| IL (1) | IL150114A0 (en) |
| IS (1) | IS6413A (en) |
| MX (1) | MXPA02006329A (en) |
| MY (1) | MY134008A (en) |
| NO (1) | NO20023013L (en) |
| NZ (1) | NZ520258A (en) |
| PE (1) | PE20010989A1 (en) |
| PL (1) | PL355752A1 (en) |
| SK (1) | SK8972002A3 (en) |
| TW (1) | TWI280240B (en) |
| UA (1) | UA74815C2 (en) |
| WO (1) | WO2001046151A1 (en) |
| YU (1) | YU47102A (en) |
| ZA (1) | ZA200204862B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10110772A1 (en) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics and PDE-IV inhibitors |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| HUP0302457A3 (en) * | 2000-12-20 | 2009-10-28 | Merck & Co Inc | Process for making substituted 8-arylquinolinium benzenesulfonate |
| ATE296630T1 (en) | 2001-06-27 | 2005-06-15 | Merck Frosst Canada Inc | SUBSTITUTED 8-ARYLCINOLINES AS PDE4 INHIBITORS |
| US7009055B2 (en) * | 2001-07-24 | 2006-03-07 | Merck & Co., Inc. | Preparation of Sulfonyl quinoline |
| WO2003024488A2 (en) * | 2001-09-19 | 2003-03-27 | Altana Pharma Ag | Combination of a pde inhibitor and a leukotriene receptor antagonist |
| CA2479069A1 (en) | 2002-03-18 | 2003-09-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
| JP2006519874A (en) * | 2003-03-05 | 2006-08-31 | セルジーン・コーポレーション | Diphenylethylene compounds and uses thereof |
| WO2005091752A2 (en) * | 2004-03-25 | 2005-10-06 | Synta Pharmaceuticals Corp. | Acrylonitrile derivatives for inflammation and immune-related uses |
| AU2006248200A1 (en) * | 2005-05-19 | 2006-11-23 | Synergenz Bioscience Limited | Methods and compositions for assessment of pulmonary function and disorders |
| CN102764440A (en) | 2006-07-05 | 2012-11-07 | 奈科明有限责任公司 | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases |
| KR20150004441A (en) * | 2006-07-07 | 2015-01-12 | 칼립시스, 인코포레이티드 | Bicyclic heteroaryl inhibitors of pde4 |
| US20080103105A1 (en) * | 2006-09-22 | 2008-05-01 | Braincells, Inc. | HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS |
| JP2010518064A (en) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Piperazine derivatives for the treatment of AD and related conditions |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| RU2569733C2 (en) | 2010-02-12 | 2015-11-27 | Раквалиа Фарма Инк. | Agonists of 5-ht4-receptors for treating dementia |
| US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| WO2013054153A1 (en) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nutlin compounds for use in he treatment of pulmonary hypertension |
| CN111406051A (en) * | 2017-09-03 | 2020-07-10 | 安吉昂生物医药公司 | Vinylheterocycles as RHO-associated coiled coil kinase (ROCK) inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| US5455252A (en) * | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| US6245774B1 (en) * | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
| JPH11209350A (en) * | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | Nitrogen-containing heterocyclic derivative and medicine containing the same |
-
2000
- 2000-12-19 MY MYPI20005965A patent/MY134008A/en unknown
- 2000-12-20 HU HU0203896A patent/HUP0203896A3/en unknown
- 2000-12-20 UA UA2002076108A patent/UA74815C2/en unknown
- 2000-12-20 SK SK897-2002A patent/SK8972002A3/en not_active Application Discontinuation
- 2000-12-20 DZ DZ003244A patent/DZ3244A1/en active
- 2000-12-20 NZ NZ520258A patent/NZ520258A/en unknown
- 2000-12-20 PL PL00355752A patent/PL355752A1/en not_active IP Right Cessation
- 2000-12-20 JP JP2001547062A patent/JP3782011B2/en not_active Expired - Fee Related
- 2000-12-20 AU AU23362/01A patent/AU778531B2/en not_active Ceased
- 2000-12-20 GE GE4903A patent/GEP20053626B/en unknown
- 2000-12-20 CA CA002393749A patent/CA2393749C/en not_active Expired - Fee Related
- 2000-12-20 EA EA200200702A patent/EA004747B1/en not_active IP Right Cessation
- 2000-12-20 EE EEP200200342A patent/EE200200342A/en unknown
- 2000-12-20 CN CNB00818951XA patent/CN1221534C/en not_active Expired - Fee Related
- 2000-12-20 EP EP00986937A patent/EP1244628A1/en not_active Withdrawn
- 2000-12-20 CO CO00096650A patent/CO5261613A1/en not_active Application Discontinuation
- 2000-12-20 IL IL15011400A patent/IL150114A0/en unknown
- 2000-12-20 BR BR0016651-0A patent/BR0016651A/en not_active IP Right Cessation
- 2000-12-20 WO PCT/CA2000/001559 patent/WO2001046151A1/en active IP Right Grant
- 2000-12-20 YU YU47102A patent/YU47102A/en unknown
- 2000-12-20 KR KR1020027008079A patent/KR20020082839A/en not_active Application Discontinuation
- 2000-12-20 MX MXPA02006329A patent/MXPA02006329A/en not_active Application Discontinuation
- 2000-12-20 CZ CZ20022171A patent/CZ20022171A3/en unknown
- 2000-12-21 AR ARP000106867A patent/AR029214A1/en not_active Application Discontinuation
- 2000-12-21 TW TW089127506A patent/TWI280240B/en not_active IP Right Cessation
- 2000-12-22 PE PE2000001396A patent/PE20010989A1/en not_active Application Discontinuation
-
2002
- 2002-06-11 IS IS6413A patent/IS6413A/en unknown
- 2002-06-18 ZA ZA200204862A patent/ZA200204862B/en unknown
- 2002-06-19 BG BG106840A patent/BG65403B1/en unknown
- 2002-06-21 HR HR20020545A patent/HRP20020545A2/en not_active Application Discontinuation
- 2002-06-21 NO NO20023013A patent/NO20023013L/en unknown
-
2004
- 2004-01-26 HK HK04100511A patent/HK1057560A1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02006329A (en) | Substituted 8arylquinoline phosphodiesterase4 inhibitors. | |
| FI953968A0 (en) | Anthranilic acid derivatives | |
| ATE342256T1 (en) | CHINAZOLINE DERIVATIVES AS MEDICATIONS | |
| DE60140456D1 (en) | AZA HETEROCYCLIC DERIVATIVES AND ITS THERAPEUTIC USE | |
| CA2078790A1 (en) | 3-benzylidene-1-carbamoyl-2-pyrrolidone analogues | |
| CA2083913A1 (en) | Piperazinyl-and piperidinyl-cyclohexanols | |
| ATE206412T1 (en) | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | |
| ATE323717T1 (en) | PIPERAZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND MDM2 | |
| DE60142934D1 (en) | PHARMACEUTICAL DOPAMINE-GLYCOCONJUGATE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
| CA2167382A1 (en) | Novel Fused Indan Derivative and Pharmaceutically Acceptable Salt thereof | |
| KR910007883A (en) | Quinoline derivatives, preparation method and use thereof | |
| AU6366386A (en) | 3-vinyl- and 3- ethinyl-beta-carboline derivatives their production and their use as drugs | |
| NO307883B1 (en) | Antibacterial pyridone carboxylic acid derivatives | |
| BG101601A (en) | Pharmaceutical piperazine compounds | |
| DK1155012T3 (en) | Dihydroquinazoline derivatives with anti-cancer activity | |
| DE69813886D1 (en) | NAPHTHALINE DERIVATIVES | |
| ATE480533T1 (en) | VARIOLINE DERIVATIVES AND THEIR USE AS CYTOSTATICS | |
| GB2334032A (en) | Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumour agents | |
| TR200103215T2 (en) | 6 - [[(aryl and heteroaryl) oxy] methyl] naphthalene-2-carboxyimidamide derivatives, their preparation and therapeutic applications | |
| TW200407315A (en) | Pyrimidine derivatives | |
| TR200002757T2 (en) | Indol derivatives with an anti-virus activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |